Drug class
Hydroxyacid oxidase 1 (HAO1) gene-directed small interfering RNA (siRNA); RNA interference therapy
Mechanism of action
A GalNAc-conjugated siRNA is taken up by hepatocytes and directs RISC-mediated degradation of HAO1 mRNA, reducing hepatic glycolate oxidase and decreasing glyoxylate and oxalate production.
General use cases
- Treatment of primary hyperoxaluria type 1 (PH1) in adults and paediatric patients to reduce urinary and plasma oxalate; dosing and use depend on age, weight and kidney function under the product label
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
